ACR on Air cover image

33. B-Cell Depleting Therapies and COVID-19

ACR on Air

00:00

The Benefits of Ever Shield for Immunosuppressed Patients

The length between the last dose of retuximab sort of plays a big role in, you know, how likely you are to respond to vaccines. Maybe getting a added doses, especially if you're further out from the initial dose might help. Anything else that patients on B cell depleting therapies can do to try to mitigate the risk of COVID infection? Yeah, so this goes into now probably the biggest saving grace for our immunosuppressed patients, and that's the ever Shield. Ever shield is a combination of two monoclonal antibodies that were actually isolated from two patients that had convalesced from COVID-19.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app